OICR is supporting four new research studies that aim to deliver cutting-edge innovations by maximizing the impact of existing research and making the most out of patient contributions.

A sweat-monitoring wearable device developed by UC Irvine researchers enables real-time and continuous tracking of a variety of health conditions through sweat analysis. The sensor is designed to be worn continuously outside of laboratory or clinical settings and can detect molecules in perspiration that are signs of stress, cancer, kidney disease and mental health issues. The project was funded by the UC Irvine Samueli School of Engineering.

Occupational burnout is a growing threat to care quality, workforce retention and physician well-being. Pregnant and postpartum physicians-in-training are especially at risk, facing stigma, limited support, and physical demands, alongside major role transitions and increased responsibilities at home. Investigators at Mass General Brigham conducted a randomized controlled trial showing that a parental support package consisting of a wearable breast pump, digital perinatal care access, a smart bassinet and faculty mentorship significantly reduces burnout in physician trainees. The results are published in JAMA.

Physicians and researchers at Winship Cancer Institute of Emory University announced today they have administered the first investigational in vivo CAR-T cell therapy in the United States for relapsed and refractorymultiple myeloma, marking an important milestone in the development of next-generation cellular therapies. 

Mouth stem cell proteins work by tackling a key weakness in how the cancer defends itself.  

In this real‑world multicenter study (Wenzhou, China), 113 chronic hepatitis C patients received colbopasvir (60 mg) + sofosbuvir (400 mg) daily for 12 weeks. Overall SVR12 was 99.1% (112/113). SVR12 was 100% for genotypes 3a, 3b, 6a, and compensated cirrhosis, 93.3% for genotype 1b, and 90% for HBV co‑infection. Liver function (ALBI) and fibrosis scores (FIB‑4, APRI) significantly improved. No serious adverse events occurred. The colbopasvir + sofosbuvir regimen showed excellent effectiveness and safety across diverse genotypes (including difficult‑to‑treat genotype 3b) and comorbidities.